You are here: Home » News-IANS » Health-Medicine
Business Standard

Eye injections a thing of past soon?

IANS  |  London 

In what could be a breakthrough for the millions worldwide suffering from age-related eye disorders, scientists have found that drugs could be successfully administered by eye drops rather than unpleasant and expensive eye injections.

The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months.

The new research demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the age-related macular degeneration (AMD) drug Avastin and deliver significant concentrations to the back of the eye.

"The development of eye drops that can be safely and effectively used in patients would be a magic bullet - a huge breakthrough in the treatment of AMD and other debilitating eye disorders," said professor Francesca Cordeiro from the Institute of Ophthalmology at the University College London.

One in five people over 75 have age-related macular degeneration worldwide.

Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology owing to the presence of anatomical barriers.

The researchers showed in animal models a formulation system to get substances including Avastin across the barriers in the eye and transport them across the cells of the cornea.

"All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients," added Ben Davis from the university's institute of ophthalmology.

The research was published in nanotechnology journal Small.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, March 06 2014. 13:00 IST